antifungal susceptibility testing – Page 3

First human case of Eidernor doerrieniae colonization in a peritoneal dialysis catheter: A warning from silent contamination

mycolabadmin

A 52-year-old dialysis patient noticed brownish particles inside his peritoneal dialysis catheter. Doctors identified a rare fungus called Eidernor doerrieniae using DNA sequencing, which had never been found in humans before. The catheter was removed and the patient received antifungal medications that successfully eliminated the infection without causing serious complications.

Spread of Antifungal-Resistant Trichophyton indotineae, United Kingdom, 2017–2024

mycolabadmin

A fungal infection called Trichophyton indotineae, which originated in Asia, is rapidly spreading throughout the United Kingdom and becoming resistant to common antifungal treatments. The infection typically starts in the groin area and can spread to other parts of the body, and many cases fail to respond to standard antifungal drugs like terbinafine. Researchers tracked 157 cases over seven years and found the fungus now accounts for over a third of all dermatophyte infections sent to the UK reference laboratory. Doctors and laboratory professionals are being urged to recognize this emerging threat and consider better diagnostic and treatment strategies.

Rasamsonia argillacea brain abscess in a lung transplant recipient: an unexpected infection by an unusual fungal pathogen

mycolabadmin

A 65-year-old woman who received a lung transplant developed a serious brain infection caused by a rare fungus called Rasamsonia argillacea. Doctors initially struggled to identify this unusual fungus and treated her with multiple antifungal medications, but the infection proved difficult to control because the fungus was resistant to common antifungal drugs. Investigations revealed that the patient had an undiagnosed immune system disorder called chronic granulomatous disease, which made her vulnerable to this rare infection. Despite aggressive treatment including surgery and powerful antifungal medications, the patient’s condition worsened and she eventually passed away.

Identification and antifungal susceptibility patterns of reference yeast strains to novel and conventional agents: a comparative study using CLSI, EUCAST and Sensititre YeastOne methods

mycolabadmin

Researchers compared three different laboratory methods for testing how well antifungal drugs work against common yeast infections. They tested 22 different yeast strains including Candida species using CLSI, EUCAST, and Sensititre YeastOne methods. The methods showed strong agreement overall, but some newer antifungal drugs like ibrexafungerp showed more variation between methods. The findings suggest these methods are reliable for guiding treatment decisions, but further standardization is needed for newer drugs.

Evaluation of Antifungal Activity Against Candida albicans Isolates From HIV-Positive Patients with Oral Candidiasis in a Major Referral Hospital, West Java, Indonesia

mycolabadmin

This study examined fungal infections in HIV-positive patients suffering from oral candidiasis (mouth thrush) in Indonesia. Researchers identified the types of Candida fungi present and tested their resistance to four common antifungal medications. Most patients had Candida albicans, and while these fungi generally responded well to newer antifungal drugs like voriconazole and fluconazole, some showed resistance, particularly to fluconazole, suggesting the need for careful testing before prescribing treatment.

Evaluation of antifungal effect of amphotericin B in comparison with nystatin on Candida species derived from patients undergoing head-and-neck radiotherapy

mycolabadmin

This study compared two antifungal medications (nystatin and amphotericin B) for treating oral yeast infections in cancer patients receiving head-and-neck radiotherapy. Researchers tested how well each drug worked against different Candida yeast species before and during radiation treatment. The results showed that nystatin was more effective than amphotericin B at killing the yeasts, with nystatin working against all yeast species tested, while amphotericin B had reduced effectiveness against some Candida albicans strains.

Pyrvinium Pamoate Synergizes with Azoles in vitro and in vivo to Exert Antifungal Efficacy Against Candida auris and Other Candida Species

mycolabadmin

Researchers tested a combination of an old antiparasitic drug called pyrvinium pamoate with common antifungal medications called azoles against dangerous drug-resistant fungal infections. While pyrvinium pamoate alone was not very effective, when combined with azoles it significantly improved the treatment of Candida auris infections. Tests in insect larvae showed that the combination improved survival rates better than using azoles alone, suggesting a promising new treatment approach for serious fungal infections.

Magnusiomyces capitatus bloodstream infection in a patient with acute monocytic leukemia: A rare case report

mycolabadmin

A 26-year-old patient with acute leukemia developed a serious fungal blood infection caused by Magnusiomyces capitatus, a rare organism found in environmental sources. The infection was confirmed using advanced molecular techniques and showed resistance to common antifungal drugs but responded to amphotericin B treatment. This case highlights how important it is for doctors to consider unusual fungi in severely immunocompromised patients and to use modern diagnostic methods for accurate identification and tailored treatment.

The Impact of the Fungal Priority Pathogens List on Medical Mycology: A Northern European Perspective

mycolabadmin

Fungal infections affect over a billion people worldwide but are often overlooked in healthcare. The World Health Organization recently created a priority list of dangerous fungi to help doctors and researchers focus their efforts. This review discusses how this list can improve diagnosis, testing, and treatment of fungal infections across Europe, while also highlighting the need for better training and awareness among healthcare workers.

Neonatal Invasive Candidiasis: Current Concepts

mycolabadmin

Neonatal invasive candidiasis is a serious fungal infection affecting premature and very low birth weight babies. The types of fungi causing these infections are changing globally, with more resistant strains appearing, especially in lower-income countries. Treatment options are limited by this resistance, making prevention through hygiene and proper hospital practices increasingly important.

Research Keyword: antifungal susceptibility testing